Skip to main content
Fig. 3 | Experimental Hematology & Oncology

Fig. 3

From: Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma

Fig. 3

Efficacy of CUDC-907 in the myeloma cells. Myeloma cells were treated with the indicated concentrations of CUDC-907 for 48 h or 72 h. The effect of CUDC-907 treatment on cellular growth (a, f), cytotoxicity (b, g), and caspase 3/7 activity (c) was evaluated. *P < 0.05 vs. control. d Myeloma cells were treated with the indicated concentration of CUDC-907 for 24 h. Total cell lysates were evaluated by immunoblotting. Results represent the mean of three independent experiments. e Myeloma cells were treated with CUDC-907 for 24 h and measured using the 20S Proteasome Assay Kit. *P < 0.05 vs. control

Back to article page